A recent randomized trial in very preterm small-for-gestational age (SGA) babies investigated whether the administration of GM-CSF could prevent neonatal sepsis and produce differences in survival free of severe disability [31]. The gene discussed is CSF2; the disease is Neonatal sepsis.